The results of this subgroup analysis of the IMPROVETM study suggest that by intensifying basal insulin regimens to a BIAsp 30 regimen in routine care, glycaemic control can be significantly improved in inadequately controlled patients with type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.